WO1984002272A1 - Antitumor composition, method for treating tumor, and use of the composition for treating tumor - Google Patents
Antitumor composition, method for treating tumor, and use of the composition for treating tumor Download PDFInfo
- Publication number
- WO1984002272A1 WO1984002272A1 PCT/JP1983/000437 JP8300437W WO8402272A1 WO 1984002272 A1 WO1984002272 A1 WO 1984002272A1 JP 8300437 W JP8300437 W JP 8300437W WO 8402272 A1 WO8402272 A1 WO 8402272A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- composition
- formula
- days
- acid addition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to an antitumor composition, a method for treating a tumor, and a use for treating a tumor.
- ESCCC Experimental tumor of Vamoy L-cystine
- S-methylcarbamoyl L-cystineethyl ester or a pharmaceutically acceptable acid addition salt thereof shown by the formula (1) has excellent effects on various experimental tumors, thereby completing the present invention.
- the compound used in the present invention is obtained by converting L-cys-ethyl ester or an acid addition salt thereof and methyl isocyanate into an inert solvent (water, ethanol, acetate, benzene, tetrahydrofuran, ethyl acetate, dimethyl acetate).
- a representative example of the compound of the present invention is S-methylcarbamoyl-L-cystinetyl ester hydrochloride (hereinafter, referred to as Y—640), which is a colorless needle having a melting point of 134-1316. Obtained as crystals.
- T indicates the average survival days of drug-treated mice
- C indicates the average survival days of untreated mice.
- mice Five female CDF type 1 mice (7-8 weeks old) were transplanted with 10 ° P-388 leukemia cells in the peritoneal cavity 1 per group. Twenty-four hours after transplantation, Y—6430 or ESCC was administered once a day for seven days, and the average number of surviving B, the survival rate, and the number of surviving animals 30 days later were determined. The results are shown in Tables 2 and 3. These results revealed that Y-634 was effective against P-388 leukemia, whereas ESCC was only marginally effective.
- L1210 leukemia cells were transplanted.
- mice were intraperitoneally administered 1 H once, and the average number of surviving B was determined. Result 9
- Y-6430 was administered intraperitoneally or subcutaneously once a day for 7 days, and the number of dead animals, the average number of surviving days, and the number of surviving animals after 30 days were determined. The results are summarized in Table 10 below.
- the acute toxicity when Y-640 was intraperitoneally administered to male ddn mice was 1,500 mg / kg or more.
- the acute toxicity value for Dongliu rats implanted with AH-44 tumor cells intraperitoneally was more than 1000 mg ZKg for both intraperitoneal and oral administration.
- the active ingredient compound of the present invention was In an experimental tumor model developed by Dell, its efficacy was confirmed by oral administration, and it is estimated that its action is different from that of existing drugs, and its usefulness as a new type of anticancer drug is expected. You. Regarding the safety of the compound, no mutagenicity was observed in reversion mutagenicity (Ames test) and DNA damage test (Rec as say), Since no toxicity is observed, it is expected to be superior in safety as compared to existing control agents.
- the active ingredient compound of the present invention is useful as an antitumor agent for various mammals including humans.
- the active ingredient compound of the present invention When used as an antibacterial agent, it is preferably mixed with pharmaceutically acceptable carriers, excipients, diluents, and other additives to form powders, granules, pharmaceutical preparations, It can take the form of dragees, capsules, syrups, suppositories, external preparations, injections, infusions, and the like.
- the antitumor agent of the present invention is administered orally or parenterally to mammals living in humans, and particularly preferred is perovaneous administration.
- the dose may be an amount that effectively inhibits the target tumor, and may vary depending on the animal to be treated, the type of tumor, the administration route, the dosage form, and the like.
- the antitumor agent of the present invention can be used in combination with other anticancer agents, immunostimulants or other acceptable drugs.
- Tablets consisting of. Sugar-coated tablets by applying sugar-coating treatment if desired
- a capsule comprising the composition of
- Fine granules consisting of
- OMPI Granules consisting of 15% starch.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57221709A JPS59110618A (ja) | 1982-12-16 | 1982-12-16 | 抗腫瘍剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1984002272A1 true WO1984002272A1 (en) | 1984-06-21 |
Family
ID=16771038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1983/000437 WO1984002272A1 (en) | 1982-12-16 | 1983-12-14 | Antitumor composition, method for treating tumor, and use of the composition for treating tumor |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0139005A4 (ja) |
JP (1) | JPS59110618A (ja) |
DE (1) | DE3390386T1 (ja) |
WO (1) | WO1984002272A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4325547A1 (de) * | 1993-07-29 | 1995-02-02 | Max Planck Gesellschaft | Verwendung von Thiolverbindungen zur Therapie von viralen Erkrankungen |
DE4406261A1 (de) * | 1993-08-31 | 1995-03-02 | Deutsches Krebsforsch | Mittel zur Verminderung der Körperfettmenge |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4329857C2 (de) * | 1993-09-03 | 1995-08-24 | Deutsches Krebsforsch | Verbindung zur Stärkung des Immunsystems und von Immunreaktionen |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49223A (ja) * | 1972-04-18 | 1974-01-05 | ||
JPS4976824A (ja) * | 1972-12-05 | 1974-07-24 | ||
JPS49135942A (ja) * | 1973-05-14 | 1974-12-27 |
-
1982
- 1982-12-16 JP JP57221709A patent/JPS59110618A/ja active Pending
-
1983
- 1983-12-14 EP EP19840900104 patent/EP0139005A4/en not_active Withdrawn
- 1983-12-14 WO PCT/JP1983/000437 patent/WO1984002272A1/ja not_active Application Discontinuation
- 1983-12-14 DE DE19833390386 patent/DE3390386T1/de not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS49223A (ja) * | 1972-04-18 | 1974-01-05 | ||
JPS4976824A (ja) * | 1972-12-05 | 1974-07-24 | ||
JPS49135942A (ja) * | 1973-05-14 | 1974-12-27 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0139005A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4325547A1 (de) * | 1993-07-29 | 1995-02-02 | Max Planck Gesellschaft | Verwendung von Thiolverbindungen zur Therapie von viralen Erkrankungen |
DE4406261A1 (de) * | 1993-08-31 | 1995-03-02 | Deutsches Krebsforsch | Mittel zur Verminderung der Körperfettmenge |
Also Published As
Publication number | Publication date |
---|---|
DE3390386T1 (de) | 1985-01-24 |
JPS59110618A (ja) | 1984-06-26 |
EP0139005A1 (en) | 1985-05-02 |
EP0139005A4 (en) | 1985-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6146455B2 (ja) | ||
WO1990002550A1 (en) | Treatment of damaged bone marrow and dosage units therefor | |
KR100442096B1 (ko) | 이중 디카르복실산 디아미노플라틴 착체의 항종양 유도체, 그의 제조방법, 그것을 함유하는 약학조성물 및 그 유도체의 적용 | |
JP4170758B2 (ja) | 骨髄抑制治療剤、感染症治療剤及び白血球数増加剤 | |
JPS6136494B2 (ja) | ||
EP0283139B1 (en) | Anticancer compounds | |
CS208660B2 (en) | Method of making the n-/2-phenyl-2-hydroxyethyl/-1,1-dimethyl-3-phenylpropylamin derivatives | |
WO1995028939A1 (fr) | Composition medicinale servant de medicament contre le cancer bronchopulmonaire 'non a petites cellules' | |
JPH0430924B2 (ja) | ||
JPH05163148A (ja) | 抗腫瘍剤 | |
WO1984002272A1 (en) | Antitumor composition, method for treating tumor, and use of the composition for treating tumor | |
JP5210888B2 (ja) | 黒色腫の治療のためのガリウム(iii)錯体の使用 | |
JPS58159489A (ja) | 2,3−ジアリ−ル−5−ハロチオフエン化合物 | |
CN108992463B (zh) | 一种治疗肺癌的组合物及药物制剂 | |
CA2684938A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
JPWO2021093839A5 (ja) | ||
JPH0633242B2 (ja) | 有機ゲルマニウム化合物を有効成分とする肝炎の治療剤 | |
RU2709491C1 (ru) | Новые производные ванадия, обладающие гипогликемической активностью | |
KR100632250B1 (ko) | 비소 화합물을 유효성분으로 하는 항암제 | |
JPH0120128B2 (ja) | ||
US20040142882A1 (en) | Use of glycyrrhizin and its derivatives as RANTES inducers | |
CN108368043A (zh) | 用于治疗及/或预防纤维化疾病的吲哚啉衍生物 | |
US5206270A (en) | Method of inhibiting melanoma cells | |
JPH08165236A (ja) | 下痢の予防及び治療剤 | |
JPH05500067A (ja) | 細胞増殖抑制剤とキサントゲナートをベースにした低毒性抗腫瘍剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): DE US |
|
AL | Designated countries for regional patents |
Designated state(s): BE DE FR GB NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1984900104 Country of ref document: EP |
|
RET | De translation (de og part 6b) |
Ref document number: 3390386 Country of ref document: DE Date of ref document: 19850124 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3390386 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 1984900104 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1984900104 Country of ref document: EP |